FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Population Pharmacokinetic and Exposure-Efficacy Analyses of Valbenazine in Patients with Huntington's Disease: Supporting Dose Selection for Chorea Management. PMID 40796529 · J Clin Pharmacol · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial. PMID 40796479 · Eur Urol · 2025-Dec The study is a randomized Phase 3 trial in oncology, but it investigates a surgical intervention (non-drug) and reports functional outcomes, not the required time-to-event efficacy endpoints. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A phase 3, randomized, double-blind, active-controlled clinical study to compare BAT2206, a ustekinumab biosimilar, with ustekinumab reference product in patients with moderate-to-severe psoriasis: Treatment period 2 results (post Week 28 to Week 52). PMID 40784561 · J Am Acad Dermatol · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The evolution of treatment for pediatric advanced stage classic Hodgkin lymphoma - a narrative literature review. PMID 40776670 · Leuk Lymphoma · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Pharmacokinetics of subcutaneous and intravenous bolus doses of morphine in palliative care cancer patients receiving infusion of morphine: A pharmacokinetic substudy of a randomized controlled trial. PMID 40755222 · Br J Clin Pharmacol · 2025-Dec The record is a pharmacokinetic substudy of a randomized trial in palliative care cancer patients. It does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, etc.). The phase is not explicitly stated as Phase III/IIIb or Phase II/III. The focus is on pharmacokinetics, not drug intervention efficacy. Therefore, it does not meet eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis. PMID 40752754 · Am J Obstet Gynecol · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Hybrid Design Incorporating External Data to Evaluate Dexamethasone Intracameral Drug Delivery Suspension for Post-Cataract Surgery Inflammation. PMID 40745864 · Clin Pharmacol Ther · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Time Dependence of Outcomes in the SPCG-4 Randomized Trial Comparing Radical Prostatectomy and Watchful Waiting in Early Prostate Cancer. PMID 40744802 · Eur Urol · 2025-Dec The record describes a randomized Phase III oncology trial with long-term time-to-event outcomes (prostate cancer mortality). However, it is excluded because it does not involve a drug-containing intervention (surgery vs. observation), which is a required criterion for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial. PMID 40713359 · Eur Urol · 2025-Dec The record is a title-only entry for a Phase 3 randomized trial in oncology. However, it fails multiple eligibility criteria based on available metadata: (1) No abstract or text to confirm a time-to-event efficacy endpoint (time_to_event: false). (2) The intervention described is surgical (RARP) with no explicit drug component (drug_intervention: false). (3) The 'Re:' prefix in the title and absence of abstract suggest this may not be the original primary result publication (original_result: false). Therefore, it is not eligible. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma. PMID 40708270 · Leuk Lymphoma · 2025-Dec This is a matching-adjusted indirect comparison (MAIC) of two separate CAR-T therapies, not a primary result report of a single randomized trial. While it references Phase III trials, it does not present original trial data for a single intervention. The efficacy analysis focuses on comparing hazard ratios or specific time-to-event outcomes between the two products, but the abstract does not explicitly report or analyze such endpoints (e.g., OS, PFS) for the purpose of this comparison; it states 'no statistically significant differences' without detailing the metric. Therefore, it does not meet the core criterion of being an original formal-result report of a single randomized trial with a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study. PMID 40706710 · J Thorac Oncol · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies. PMID 40704461 · Aliment Pharmacol Ther · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of kidney function on 200 days of antiviral prophylaxis for cytomegalovirus disease in cytomegalovirus-seronegative recipients of cytomegalovirus-seropositive donor kidneys: Post hoc analysis of a randomized, phase 3 trial of letermovir vs valganciclovir prophylaxis. PMID 40701254 · Am J Transplant · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Thirty-Five-Year Follow-Up Real-World Data Revealed the Efficacy of Autologous Formalin-Fixed Tumor Vaccine on Metastatic Breast Cancer-A Target Trial Emulation. PMID 40695705 · Clin Breast Cancer · 2025-Dec This is a retrospective real-world study using target trial emulation, not a randomized controlled trial. It lacks explicit confirmation of being a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention as defined by the protocol. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics. PMID 40683616 · Am Heart J · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9-14 years compared with three doses of quadrivalent HPV vaccine in women aged 18-25 years in Costa Rica (PRIMAVERA): a non-randomised, open-label, immunobridging, non-inferiority trial. PMID 40683285 · Lancet Infect Dis · 2025-Dec The record describes a non-randomized, immunobridging trial with immunogenicity endpoints (antibody concentrations and seropositivity), not a randomized trial with a time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Analytical and Clinical Performance of the VENTANA CLDN18 (43-14A) RxDx Assay in Gastric and Gastroesophageal Junction Adenocarcinoma Tissue Samples in SPOTLIGHT and GLOW. PMID 40680855 · Mod Pathol · 2025-Dec The record describes the performance of a diagnostic assay in the context of Phase III trials but does not appear to be a primary or secondary efficacy result report of the trials themselves. It lacks explicit evidence of randomization and does not present the efficacy data in a way suitable for KM digitization. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Design and rationale of the HARTc 2.0 trial: A multicenter randomized controlled study on the impact of point-of-care high-sensitivity cardiac troponin-I testing in prehospital acute coronary syndrome triage on diagnosis and cost-effectiveness. PMID 40675207 · Am Heart J · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study. PMID 40675167 · Lancet Infect Dis · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of moxidectin-albendazole combination therapy for Trichuris trichiura infections in school-aged children: a double-blind, randomised, controlled, superiority trial. PMID 40675166 · Lancet Infect Dis · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Swallowing and Communication Outcomes Post Chemoradiotherapy for Low-Risk Human Papillomavirus (HPV)-Associated Oropharyngeal Squamous Cell Carcinoma: A Substudy of TROG 12.01. PMID 40662470 · Head Neck · 2025-Dec The study is a substudy of a Phase III randomized trial but reports on swallowing and communication outcomes, not on a primary/key secondary time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the inclusion criteria for a Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Prophylactic Versus Reactive (PvR) Feeding in Patients Undergoing (Chemo)radiation in Head and Neck Cancers: Results of a Phase III Randomized Controlled Trial. PMID 40662454 · Head Neck · 2025-Dec The trial is an oncology Phase III randomized controlled trial with original results, but it lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoint is incidence of significant weight loss at 6 months, a categorical outcome, not time-to-event. Additionally, the intervention is a non-drug feeding strategy, not a drug-containing intervention. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sublingual Ketamine as Breakthrough Analgesia in Patients with Advanced Cancer-A Feasibility Randomised Controlled Repeated Cross-over Trial. PMID 40650554 · J Pain Palliat Care Pharmacother · 2025-Dec The study is a randomized controlled feasibility/pilot trial, not a definitive Phase III or Phase II/III trial. The intervention (sublingual ketamine) is for pain management, not as an anti-cancer drug. The primary endpoint is feasibility (attrition rate), not a time-to-event oncology efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Study of the effectiveness of different pelvic floor muscle training methods for improving urinary incontinence in patients with prostate cancer after radical prostatectomy. PMID 40642816 · Aging Male · 2025-Dec The study is a randomized controlled trial in human oncology (prostate cancer), but the interventions are non-drug (pelvic floor muscle training and magnetic stimulation), and the primary efficacy outcomes are based on urinary incontinence scores and pad tests, not time-to-event endpoints like OS, PFS, DFS, etc. Therefore, it does not meet the inclusion criteria for a drug-containing intervention with a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| New targets in diabetic retinopathy: addressing limitations of current treatments through the Sema3A/Nrp1 pathway. PMID 40634736 · Eye (Lond) · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A Randomized Controlled Trial of Silver Diamine Fluoride Application Time. PMID 40583169 · J Dent Res · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure-Response Relationship during Treatment of Obesity with Tirzepatide. PMID 40556483 · Clin Pharmacol Ther · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrent Clostridioides difficile infection. PMID 40552763 · Gut Microbes · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up. PMID 40537903 · Hum Vaccin Immunother · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The effects of music therapy on pain and anxiety in young nulliparous patients undergoing laparoscopic cystectomy for endometriosis: a randomized controlled trial. PMID 40534482 · J Psychosom Obstet Gynaecol · 2025-Dec 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tenecteplase in Central Retinal Artery Occlusion Study (TenCRAOS): Protocol for a randomized-controlled trial. PMID 40509553 · Eur Stroke J · 2025-Dec 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Prehabilitation during neoadjuvant chemotherapy results in an enhanced immune response in esophageal adenocarcinoma tumors: A randomized controlled trial. PMID 40499717 · J Sport Health Sci · 2025-Dec The study is a randomized controlled trial in human esophageal adenocarcinoma with a drug-containing intervention (neoadjuvant chemotherapy) and reports clinical outcomes, but it does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) as a primary or key secondary outcome; the primary outcome is tumor immune response (TILs), and clinical outcomes like survival are mentioned only as exploratory without formal analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| RhTSH in aiding dynamic assessment in patients with differentiated thyroid Cancer. PMID 40488858 · Eur J Nucl Med Mol Imaging · 2025-Dec The study is a phase 3 randomized trial in human oncology with a drug intervention and reports original results, but it is not randomized (self-controlled design) and does not include a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage. PMID 40488446 · Eur J Heart Fail · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| TALON Phase IIIb Study: 32-Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age-Related Macular Degeneration. PMID 40466770 · Ophthalmol Retina · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Dostarlimab and niraparib in primary advanced ovarian cancer. PMID 40461381 · Ann Oncol · 2025-Dec 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Comparative immune response of Typbar TCV® (typhoid conjugate vaccine) in extremes of age: An Indian experience. PMID 40445123 · Hum Vaccin Immunother · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Peripheral Blood Gene Expression Profiling and Prognostic Significance for the Course of Interstitial Lung Disease in Patients With Systemic Sclerosis. PMID 40420438 · Arthritis Rheumatol · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China. PMID 40417858 · Arthritis Rheumatol · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Colombia. PMID 40417835 · J Med Econ · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial. PMID 40376714 · Hum Vaccin Immunother · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Self-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder. PMID 40331914 · Eur J Psychotraumatol · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a 3-Month Follow-up of a Prospective, Open Label, Single-Center Study. PMID 40325343 · Transl Stroke Res · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of Immune Checkpoint Inhibitors as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis. PMID 40288918 · Eur Urol Oncol · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial. PMID 40263079 · Eur Urol Oncol · 2025-Dec 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Safety profile of self-amplifying mRNA SARS-CoV-2 vaccine ARCT-154 in adults: a pooled phase 1/2/3 randomized clinical study. PMID 40195167 · Expert Rev Vaccines · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers. PMID 40174609 · Hum Vaccin Immunother · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel in Hispanic participants with moderate-to-severe acne: a pooled analysis. PMID 40122140 · J Dermatolog Treat · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effects of exercise on inflammation, circulating tumor cells, and circulating tumor DNA in colorectal cancer. PMID 40107449 · J Sport Health Sci · 2025-Dec The study is a randomized trial in oncology (colorectal cancer) but is ineligible because it lacks a drug intervention (exercise-only) and does not report a primary or key secondary time-to-event efficacy endpoint. The endpoints are biomarker changes. The trial phase is also not definitively established as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages. PMID 39998495 · Emerg Microbes Infect · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |